Company intelligence / Profile preview
Intellia Therapeutics
Cambridge, Massachusetts, United Statesintelliatx.com ↗
- Ownership
- Public · NTLA
- Employees
- ~598
- Development stage
- Other
01
Overview
Intellia has two in vivo programs in ongoing clinical trials: NTLA-2001 for ATTR amyloidosis (Phase 1) and NTLA-2002 for hereditary angioedema (Phase 1/2). The company uses proprietary non-viral gene knockout platform with lipid nanoparticles to deliver CRISPR/Cas9 components.
- Therapeutic areas
- OncologyHematologyImmunologyRare Diseases
- Modalities
- CRISPR/Cas9 gene editingIn vivo therapeuticsEx vivo therapeutics
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $1.6B
- Total revenue
- $67.7M
- Enterprise value
- $940.9M
Beyond the preview
Go deeper on Intellia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intellia Therapeutics.